Telomir Pharmaceuticals
TELO | NASDAQ
$0.49
-$0.01 (-2.08%)
At close: Nov 13, 2026, 4:00 PM ET
$0.50
+$0.01 (+2.45%)
After-hours:
Nov 13, 2026, 7:30 PM ET
-2.08%
(1D)No price chart data available for 1D timeframe.
Rating
28.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #833/1022 (Top 82%)
Key Statistics
Market Data
Market Cap $36.15M
1D Range
0.49 0.57
52W Range
0.49 1.49
Valuation (TTM)
PE -0.33
PB 8.21
EV/EBITDA -6.63
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $4.00
Cash Flow
FCF Yield -12.7%
SBC Adj. FCF Yield -13.5%
SBC Impact -6.6%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y -38.8% |
N/A
FCF 3Y | 5Y 11.1% |
N/A
Returns
ROA -118.0%
ROE -107.9%
ROIC -129.1%
Financial Health
Net Cash
$4.52M
Current Ratio 19.60
Interest Coverage -918.41
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the d...
Sector Healthcare
Industry Biotechnology
Employees 2
IPO Date Feb 9, 2024
Website telomirpharma.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove TELO